Pharvaris’ (PHVS) “Overweight” Rating Reaffirmed at Morgan Stanley

Morgan Stanley reiterated their overweight rating on shares of Pharvaris (NASDAQ:PHVS) in a research report released on Monday, Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.

A number of other analysts have also recently weighed in on PHVS. Wedbush reissued an outperform rating and issued a $35.00 target price on shares of Pharvaris in a research note on Thursday, April 11th. JMP Securities upped their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the stock a market outperform rating in a research note on Thursday, April 11th.

Pharvaris Stock Up 8.9 %

NASDAQ PHVS opened at $20.87 on Monday. The stock has a market cap of $664.50 million, a P/E ratio of -7.35 and a beta of -3.12. The company’s 50-day simple moving average is $23.85 and its 200 day simple moving average is $23.33. Pharvaris has a twelve month low of $7.93 and a twelve month high of $33.00.

Institutional Investors Weigh In On Pharvaris

Hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP acquired a new stake in Pharvaris in the third quarter worth $812,000. Walleye Capital LLC raised its holdings in Pharvaris by 15.2% in the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after purchasing an additional 10,691 shares during the period. Blackstone Inc. acquired a new stake in Pharvaris in the fourth quarter worth $2,805,000. Vivo Capital LLC acquired a new stake in Pharvaris in the fourth quarter worth $7,994,000. Finally, Commodore Capital LP acquired a new stake in Pharvaris in the fourth quarter worth $22,440,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).